Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 7
Submit an article Journal homepage
222
Views
21
CrossRef citations to date
0
Altmetric
Original Articles: Research

Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737

Aarthi Jayanthan Hughes' Children's Cancer Research Centre and the Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, CanadaCorrespondence[email protected]
,
Scott C. Howard St. Jude Children's Research Hospital, Memphis, Tennessee, USA
,
Tanya Trippett Memorial Sloane-Kettering Cancer Center, New York, New York, USA
,
Terzah Horton Baylor College of Medicine, Houston, Texas, USA
,
James A. Whitlock Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
Lara Daisley Hughes' Children's Cancer Research Centre and the Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada
,
Victor Lewis Hughes' Children's Cancer Research Centre and the Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada
&
Aru Narendran Hughes' Children's Cancer Research Centre and the Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada
 show all
Pages 1174-1182 | Received 12 Sep 2008, Accepted 31 Mar 2009, Published online: 21 Jul 2009

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Donatella Aldinucci, Annunziata Gloghini, Antonio Pinto, Alfonso Colombatti & Antonino Carbone. (2012) The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leukemia & Lymphoma 53:2, pages 195-201.
Read now
Lindsay C Spender & Gareth J Inman. (2009) Targeting the BCL-2 family in malignancies of germinal centre origin. Expert Opinion on Therapeutic Targets 13:12, pages 1459-1472.
Read now
Seong L. Khaw, David C. S. Huang & Andrew W. Roberts. (2009) BH3-mimetics – the solution to chemoresistance?. Leukemia & Lymphoma 50:7, pages 1069-1072.
Read now

Articles from other publishers (18)

Myra Langendonk, Nienke A. M. Smit, Wouter Plattel, Arjan Diepstra, Tom van Meerten & Lydia Visser. (2022) Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma. International Journal of Molecular Sciences 23:22, pages 13751.
Crossref
Linlin Zhang, Zaiming Lu & Xiangxuan Zhao. (2021) Targeting Bcl-2 for cancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:1, pages 188569.
Crossref
Clare M. Adams, Ramkrishna Mitra, Ashley N. Vogel, Jinglan Liu, Jerald Z. Gong & Christine M. Eischen. (2019) Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma. Leukemia 34:3, pages 947-952.
Crossref
L. Porcelli, D. Stolfa, A. Stefanachi, R. Di Fonte, M. Garofoli, R.M. Iacobazzi, N. Silvestris, A. Guarini, S. Cellamare & A. Azzariti. (2019) Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. Cancer Letters 445, pages 1-10.
Crossref
Huanling Wu, L. Jeffrey Medeiros & Ken H. Young. (2018) Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Reviews 32:1, pages 8-28.
Crossref
Peter H. Wiernik. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 903 937 .
Khurum H. Khan, Montserrat Blanco-Codesido & L. Rhoda Molife. (2014) Cancer therapeutics: Targeting the apoptotic pathway. Critical Reviews in Oncology/Hematology 90:3, pages 200-219.
Crossref
Fengzhi Li. 2013. 217 252 .
Victor Y. Yazbeck & Daniel E. Johnson. 2013. Cell Death Signaling in Cancer Biology and Treatment. Cell Death Signaling in Cancer Biology and Treatment 231 253 .
Peter H. Wiernik, Monica Balzarotti & Armando Santoro. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 985 1013 .
S Ackler, MJ Mitten, J Chen, J Clarin, K Foster, S Jin, DC Phillips, S Schlessinger, B Wang, JD Leverson & ER Boghaert. (2012) Navitoclax (ABT-263) and bendamustine ? rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo . British Journal of Pharmacology 167:4, pages 881-891.
Crossref
Anjali Singh, Aarthi Jayanthan, Allyson Farran, Adam N. Elwi, Sung-Woo Kim, Peter Farran & Aru Narendran. (2011) Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition. Leukemia Research 35:12, pages 1649-1657.
Crossref
Jagat R. Kanwar, Sishir K. Kamalapuram & Rupinder K. Kanwar. (2011) Targeting survivin in cancer: the cell-signalling perspective. Drug Discovery Today 16:11-12, pages 485-494.
Crossref
Aarthi Jayanthan, Andrea Incoronato, Anjali Singh, Christopher Blackmore, Delphine Bernoux, Victor Lewis, Ronald Stam, James. A. Whitlock & Aru Narendran. (2011) Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement . Pediatric Blood & Cancer 56:3, pages 353-360.
Crossref
David Reynoso, Laura K. Nolden, Dan Yang, Sarah N. Dumont, Anthony P. Conley, Amaury G.P. Dumont, Kim Zhou, Anette Duensing & Jonathan C. Trent. (2011) Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Molecular Oncology 5:1, pages 93-104.
Crossref
J Lian, X Wu, F He, D Karnak, W Tang, Y Meng, D Xiang, M Ji, T S Lawrence & L Xu. (2010) A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2–Beclin1 interaction at endoplasmic reticulum. Cell Death & Differentiation 18:1, pages 60-71.
Crossref
Beatriz Sánchez-EspiridiónCarlos MontalbánÁngel LópezJavier MenárguezPilar SabínCarmen Ruiz-MarcellánAndrés LopezRafael RamosJose RodríguezAraceli CánovasCarmen CamareroMiguel CanalesJavier AlvesReyes ArranzAgustín AcevedoAntonio SalarSergio SerranoÁgueda BasJose M. MoraledaPedro Sánchez-GodoyFernando BurgosConcepción RayónManuel F. FresnoJosé García LarañaMónica García-CosíoCarlos SantonjaJose L. LópezMarta LlanosManuela MollejoJoaquín González-CarreroAna MarínJerónimo FortezaRamón García-Sanz, Jose F. Tomás, Manuel M. MorenteMiguel A. PirisJuan F. García. (2010) A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 116:8, pages e12-e17.
Crossref
Vladimír Vonka. (2010) Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2:2, pages 227-241.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.